Minerva Neurosciences is a clinical-stage biopharmaceutical company which focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The Company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia. It also offers a number of product candidates for treating primary insomnia, major depressive disorder and Parkinson's disease.